Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Intangibles (2017 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Intangibles for 9 consecutive years, with $176.0 million as the latest value for Q4 2025.

  • Quarterly Intangibles fell 1.12% to $176.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $176.0 million through Dec 2025, down 1.12% year-over-year, with the annual reading at $176.0 million for FY2025, 1.12% down from the prior year.
  • Intangibles for Q4 2025 was $176.0 million at Ultragenyx Pharmaceutical, up from $172.9 million in the prior quarter.
  • The five-year high for Intangibles was $178.0 million in Q4 2024, with the low at $130.8 million in Q4 2021.
  • Average Intangibles over 5 years is $159.2 million, with a median of $160.0 million recorded in 2022.
  • The sharpest move saw Intangibles increased 22.42% in 2022, then fell 1.12% in 2025.
  • Over 5 years, Intangibles stood at $130.8 million in 2021, then grew by 22.42% to $160.1 million in 2022, then grew by 8.54% to $173.8 million in 2023, then increased by 2.43% to $178.0 million in 2024, then fell by 1.12% to $176.0 million in 2025.
  • According to Business Quant data, Intangibles over the past three periods came in at $176.0 million, $172.9 million, and $174.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.